mutation surveyor dna variant analysis software v5.1.2 (SoftGenetics)
90
Structured Review
SoftGenetics
mutation surveyor dna variant analysis software v5.1.2
Mutation Surveyor Dna Variant Analysis Software V5.1.2, supplied by SoftGenetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutation+surveyor+dna+variant+analysis+software+v5%2E1%2E2/mutation+surveyor+software/pm40138980-121-7-14
Average 90 stars, based on 1 article reviews
Mutation Surveyor Dna Variant Analysis Software V5.1.2, supplied by SoftGenetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mutation+surveyor+dna+variant+analysis+software+v5%2E1%2E2/mutation+surveyor+software/pm40138980-121-7-14
Average 90 stars, based on 1 article reviews
mutation surveyor dna variant analysis software v5.1.2 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Sequencing:Article Title: Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing. Article Snippet: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (α-Gal A) due to pathogenic variants of the GLA gene.. This study reports findings from data collected through The Lantern Project, including results from α-Gal A enzyme activity and globotriaosylsphingosine (lyso-Gb3) biomarker assays from dried blood spots, as well as next-generation sequencing (NGS).. A total of 513 enzyme tests, 284 lyso-Gb3 tests, and 994 NGS tests were conducted on 1380 individuals (708 female, 661 male, 11 sex unknown) with clinical suspicion, or family history or abnormal newborn screening (NBS) results who participated in the project from December 2018–April 2023. Mutagenesis:Article Title: Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing. Article Snippet: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (α-Gal A) due to pathogenic variants of the GLA gene.. This study reports findings from data collected through The Lantern Project, including results from α-Gal A enzyme activity and globotriaosylsphingosine (lyso-Gb3) biomarker assays from dried blood spots, as well as next-generation sequencing (NGS).. A total of 513 enzyme tests, 284 lyso-Gb3 tests, and 994 NGS tests were conducted on 1380 individuals (708 female, 661 male, 11 sex unknown) with clinical suspicion, or family history or abnormal newborn screening (NBS) results who participated in the project from December 2018–April 2023. Variant Assay:Article Title: Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing. Article Snippet: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (α-Gal A) due to pathogenic variants of the GLA gene.. This study reports findings from data collected through The Lantern Project, including results from α-Gal A enzyme activity and globotriaosylsphingosine (lyso-Gb3) biomarker assays from dried blood spots, as well as next-generation sequencing (NGS).. A total of 513 enzyme tests, 284 lyso-Gb3 tests, and 994 NGS tests were conducted on 1380 individuals (708 female, 661 male, 11 sex unknown) with clinical suspicion, or family history or abnormal newborn screening (NBS) results who participated in the project from December 2018–April 2023. Software:Article Title: Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing. Article Snippet: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (α-Gal A) due to pathogenic variants of the GLA gene.. This study reports findings from data collected through The Lantern Project, including results from α-Gal A enzyme activity and globotriaosylsphingosine (lyso-Gb3) biomarker assays from dried blood spots, as well as next-generation sequencing (NGS).. A total of 513 enzyme tests, 284 lyso-Gb3 tests, and 994 NGS tests were conducted on 1380 individuals (708 female, 661 male, 11 sex unknown) with clinical suspicion, or family history or abnormal newborn screening (NBS) results who participated in the project from December 2018–April 2023. |